Candel Therapeutics, Inc. (CADL)
NASDAQ: CADL · Real-Time Price · USD
8.91
-0.03 (-0.34%)
At close: May 14, 2026, 4:00 PM EDT
8.81
-0.10 (-1.12%)
After-hours: May 14, 2026, 5:29 PM EDT
Candel Therapeutics Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
55
Market Cap
652.84M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | - | - | - |
| Dec 31, 2024 | - | - | - |
| Dec 31, 2023 | - | - | - |
| Dec 31, 2022 | 125.00K | - | - |
| Dec 31, 2021 | 125.00K | - | - |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Zevra Therapeutics | 122.29M |
| Gyre Therapeutics | 117.05M |
| Sutro Biopharma | 102.48M |
| Arvinas | 89.40M |
| Crescent Biopharma | 11.88M |
CADL News
- 10 hours ago - Candel Therapeutics Reports First Quarter 2026 Financial Results and Recent Corporate Highlights - GlobeNewsWire
- 1 day ago - Candel Therapeutics to Present at Upcoming Investor Conferences - GlobeNewsWire
- 10 days ago - Candel Therapeutics to Host Investor Conference Call Following Presentation of Extended Data from Phase 3 Trial of Aglatimagene Besadenovec in Localized Prostate Cancer at the American Urological Association 2026 Annual Meeting - GlobeNewsWire
- 13 days ago - Candel Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 15 days ago - Candel Therapeutics Announces Commercialization Agreement with EVERSANA to Support Potential U.S. Launch of Aglatimagene Besadenovec in Localized Prostate Cancer - GlobeNewsWire
- 24 days ago - Candel Therapeutics initiated with an Overweight at Cantor Fitzgerald - TheFly
- 2 months ago - Candel Therapeutics price target raised to $26 from $22 at Citi - TheFly
- 2 months ago - Candel Therapeutics’ aglatimagene shows extended long-term survival in NSCLC - TheFly